Amedisys (AMED) Rating Increased to Strong-Buy at BidaskClub

Share on StockTwits

Amedisys (NASDAQ:AMED) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Thursday.

AMED has been the subject of a number of other research reports. Cantor Fitzgerald began coverage on shares of Amedisys in a research note on Thursday, September 13th. They set a “neutral” rating and a $117.00 target price for the company. Royal Bank of Canada lifted their target price on shares of Amedisys to $115.00 and gave the company an “outperform” rating in a research note on Friday, August 3rd. ValuEngine upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a report on Monday, July 30th. Robert W. Baird raised their price target on shares of Amedisys from $105.00 to $120.00 and gave the company a “neutral” rating in a report on Thursday, October 11th. Finally, Bank of America set a $139.00 price target on shares of Amedisys and gave the company a “buy” rating in a report on Tuesday, September 18th. Five research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. Amedisys has an average rating of “Buy” and an average target price of $105.50.

Shares of NASDAQ:AMED opened at $120.50 on Thursday. The firm has a market cap of $3.77 billion, a price-to-earnings ratio of 35.81, a P/E/G ratio of 1.76 and a beta of 1.22. Amedisys has a 12-month low of $49.80 and a 12-month high of $127.38. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.06 and a quick ratio of 1.06.

Amedisys (NASDAQ:AMED) last issued its earnings results on Monday, October 29th. The health services provider reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.18. The company had revenue of $417.34 million during the quarter, compared to analyst estimates of $411.05 million. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. The company’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter last year, the business posted $0.56 EPS. Equities analysts forecast that Amedisys will post 3.58 EPS for the current fiscal year.

In other news, insider David B. Pearce sold 398 shares of the firm’s stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $121.71, for a total transaction of $48,440.58. Following the transaction, the insider now owns 11,818 shares in the company, valued at approximately $1,438,368.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David L. Kemmerly sold 6,500 shares of the firm’s stock in a transaction on Friday, November 9th. The shares were sold at an average price of $118.87, for a total transaction of $772,655.00. The disclosure for this sale can be found here. Insiders have sold a total of 10,273 shares of company stock worth $1,217,456 in the last 90 days. 2.60% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. Glenmede Trust Co. NA raised its holdings in Amedisys by 4.3% in the 2nd quarter. Glenmede Trust Co. NA now owns 71,559 shares of the health services provider’s stock worth $6,116,000 after acquiring an additional 2,959 shares during the period. Moneta Group Investment Advisors LLC bought a new position in Amedisys in the 2nd quarter worth $181,000. Algert Global LLC bought a new position in Amedisys in the 2nd quarter worth $1,208,000. Cubist Systematic Strategies LLC raised its holdings in Amedisys by 1,086.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock worth $203,000 after acquiring an additional 2,172 shares during the period. Finally, Piedmont Investment Advisors LLC raised its holdings in Amedisys by 9.3% in the 2nd quarter. Piedmont Investment Advisors LLC now owns 6,668 shares of the health services provider’s stock worth $570,000 after acquiring an additional 567 shares during the period. Institutional investors and hedge funds own 93.58% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

See Also: What are retained earnings?

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply